Trial Profile
Phase II/III trial of Imprime PGG in patients with melanoma
Status:
Planning
Phase of Trial:
Phase II/III
Latest Information Update: 20 Apr 2016
Price :
$35
*
At a glance
- Drugs Odetiglucan (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors Biothera
- 18 Apr 2016 According to a Biothera Pharmaceuticals media release, this trial is scheduled to begin in 2016.
- 01 Mar 2016 New trial record